Preemptive Etoricoxib potentially reduces discomfort after mandibular third molar extraction, enhancing post-surgical care and patient experience.

The objective of this prospective quasi-experimental study was to assess the effects of Etoricoxib when given before and after surgery versus only after surgery, on common sequelae following third molar extraction (pain, swelling, limited mouth opening [trismus], and other inflammatory complications). Additionally, it aimed to estimate its effect on the quality of life (QoL) post-surgery.

This study included 56 individuals, divided into two groups:

• Study group: 28 participants received pre-emptive Etoricoxib 120 mg before surgery and after the surgery
• Control group: 28 participants received a pre-emptive placebo before surgery and Etoricoxib 120 mg after the surgery

The swelling, limited mouth opening, and adverse events were assessed on the 3rd and 7th day after the surgery. The visual analogue scale (VAS) and oral health-related quality of life (OHRQoL) questionnaire were used to estimate pain and QoL at specified intervals, respectively. The non-parametric tests (such as the Mann–Whitney test, Friedman test, and Wilcoxon sign test) were used for statistical analysis (significance level at P < 0.05).

The study group consistently reported lower statistically significant VAS scores during the follow-up period. The pharmacological protocol did not show a noteworthy effect on swelling and limited mouth opening after the extraction. However, administering double Etoricoxib doses notably enhanced postoperative QoL by day 3 after surgery.

The use of Etoricoxib 120 mg both before and after the third molar surgery decreased postoperative pain and improved postoperative QoL by day 3 after surgery. Notably, this approach was equally effective in reducing swelling and limited mouth opening compared to exclusively taking Etoricoxib after the surgery.